Abstract
Ischemia-reperfusion injury is one of the most important pathological outcomes observed after organ trasnplantation. Although the application of magnetic field has been proposed as a new treatment strategy for ischemic injury, there have been contraversial results reporting magnetic field treatment as being effective or uneffective on ischemic injury. This study aims to determine the therapeutic role of extremely low frequency electromagnetic field (ELF-EMF) application and the administration of pterostilbene, an antioxidant which is a derivative of resveratrol, on renal ischemic injury.In the study, rats were divided into control, ischemia-reperfusion, ELF-EMF (50 Hz, 1 mT) treatment and 10 mg/kg dose of pterostilbene injection together with magnetic field treatment groups. After the establishment of renal ischemia-reperfusion model by clamping the arteries for 20 minutes and a 24 hour reperfusion, treatments were applied for 5 consecutive days. Then the kidneys were dissected, homogenised and analyzed by Fourier transform infrared (FTIR) spectroscopy. Protein secondary structures were predicted using second derivative spectra in amide I region.Ischemia-reperfusion injury caused a decrease in lipid and protein amount, lipid/protein ratio; a decrease in the level of unsaturated lipids and unsaturated/saturated lipid ratio; an increase in membrane fluidity and lipid peroxidation in components of rat kidneys. Moreover, ischemia-reperfusion injury led to an alteration in the structure of proteins and lipids and a higher content of long chained lipids were observed in kidneys of ischemia-reperfusion group. ELF-EMF application (50 Hz, 1 mT) was not sufficient to repair all ischemia-induced alterations; however pterostilbene injection together with magnetic field treatment successfully restored ischemia-induced changes in all of the investigated parameters.The results revealed that pterostilbene treatment together with magnetic field application can be a promising prevention for renal ischemic injury.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
